A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma

This is a single-arm, open-label, dose-finding Phase I/II clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics, and pharmacodynamics of CT1190B cells in patients with R/R LBCL.

Trial Details

NCT ID
NCT07823829
Phase
PHASE1 / PHASE2
Sponsor
UCARsgen Biotech Limited
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CT1190B intravenous infusion
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Hubei, Wuhan, China|29.08114,120.41732

Key Eligibility Criteria

  • Volunteer to participate in the clinical trial; participants fully understand and are informed of this trial and sign the informed consent form; Wi…
  • Age 18 \~ 75 years (inclusive);
  • Histologically or cytologically confirmed large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma unspecified (DLBCL, NOS), primary m…
  • Has received at least 2 prior lines of standard systemic therapy and has relapsed after adequate treatment or meets refractory criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →